Copyright
©The Author(s) 2022.
World J Clin Oncol. Apr 24, 2022; 13(4): 276-286
Published online Apr 24, 2022. doi: 10.5306/wjco.v13.i4.276
Published online Apr 24, 2022. doi: 10.5306/wjco.v13.i4.276
Table 2 Phase II trials with multikinase RET inhibitors
| Drug | n | ORR | PFS | OS |
| Cabozantinib[22] | 25 | 28% | 5.5 mo | 9.9 mo |
| Vandetanib[23] | 18 | 18% | 4.5 mo | 11.6 mo |
| Lenvatinib[24] | 25 | 16% | 7.3 mo | NR |
| Sorafenib[25] | 3 | 0 | NR | NR |
| Selpercatinib[26] | 105 | 64% in platinum chemotherapy pretreated | 90% in response at 6 mo | NR |
| 85% in platinum chemotherapy naïve | ||||
| Pralsetinib[27] | 106 | 61% in platinum chemotherapy pretreated | NR | NR |
| 73% in platinum chemotherapy naïve |
- Citation: Olmedo ME, Cervera R, Cabezon-Gutierrez L, Lage Y, Corral de la Fuente E, Gómez Rueda A, Mielgo-Rubio X, Trujillo JC, Couñago F. New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2. World J Clin Oncol 2022; 13(4): 276-286
- URL: https://www.wjgnet.com/2218-4333/full/v13/i4/276.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i4.276